Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Conditions: Liver Metastasis Colon Cancer; ctDNA Genotype; MSS; Failed From Standard Treatment Interventions: Drug: HAIC+targeted therapy+PD-1 inhibitor Sponsors: Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)
Conditions: Spontaneous Bacterial Peritonitis Interventions: Drug: Rifaximin; Drug: Norfloxacin Sponsors: Institute of Liver and Biliary Sciences, India Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
Prevalence of metabolic liver disorders in children attending gastroenterology and hepatology unit at assuit university children hospital
Conditions: Metabolic Liver Disorders in Children Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
GPC3/Mesothelin-CAR- γδT Cells Against Cancers
Conditions: Pancreas Cancer; Lung Cancer; Liver Cancer; Mesothelioma; CAR-T Cell Therapy; Solid Tumor, Adult Interventions: Biological: Cell therapy for solid tumors Sponsors: Second Affiliated Hospital of Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma Non-resectable Interventions: Procedure: drug eluting beads-transcatheter arterial chemoembolization; Drug: envatinib plus anti-PD(L)1 Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC) of CC-IHPBA; Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
Conditions: Prediabetic State; Body Weight; Overweight or Obesity; Life Style, Healthy Sponsors: Jelizaveta Sokolovska; Spindox Labs; The National Research Council, Italy; The Institute of Electronics and Computer Sciences, Latvia; Euronet-Consulting; Scuola di Robotica; CheckHealth; The Italian Liver Foundation; Medical University of Graz; HK3 Lab S.R.L., Italy Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
Conditions: NASH - Nonalcoholic Steatohepatitis; NASH; Exercise; Liver Interventions: Behavioral: Exercise Intervention with use of El-Fit App Sponsors: Milton S. Hershey Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Robotic-assisted Percutaneous Transhepatic Puncture
Conditions: Liver Diseases Interventions: Device: Robotic-assisted Interventional Percutaneous transhepatic puncture Sponsors: Zhongda Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma Non-resectable Interventions: Procedure: DEB-TACE; Drug: Lenvatinib plus pucotenlimab Sponsors: Tongji Hospital; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC) of CC-IHPBA; Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Conditions: Cannabidiol; Drug Induced Liver Injury; Drug Interaction Interventions: Drug: Cannabidiol; Drug: Placebo; Drug: Citalopram; Drug: Morphine Sponsors: Food and Drug Administration (FDA); Spaulding Clinical Research LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection-phase II Clinical Trial
Conditions: Hepatocellular Carcinoma Interventions: Biological: Autologous Dendritic Cell Sponsors: Chang Gung Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Conditions: Cholangiocarcinoma Non-resectable Interventions: Procedure: HAIC; Drug: Lenvatinib plus pucotenlimab Sponsors: Ze-yang Ding, MD; Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC) of CC-IHPBA; Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
The Risk Factors for Perioperative Blood Transfusion in Open Liver Resection
Conditions: Blood Loss, Postoperative Interventions: Procedure: Open liver resection Sponsors: Chiang Mai University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Characteristics and Risk Factors for Invasive Fungal Infection With Acute-on-chronic Hepatitis B Liver Failure
Conditions: Acute-on-chronic Hepatitis B Liver Failure Sponsors: Qilu Hospital of Shandong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype
Conditions: Metastatic Colorectal Cancer; Metastatic Cancer to Liver Interventions: Radiation: [18F]-ALF-FAPI-74 PET/CT scan Sponsors: UMC Utrecht Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
